The document discusses the high failure rate and costs of drug development, and the need for new solutions to address safety and efficacy challenges. It introduces biomarkers as a key solution, noting they can help improve discovery, clinical development, and portfolio management by identifying drugs more likely to succeed in early trials. Biomarker services aim to determine proof-of-concept earlier at lower cost by providing predictive indicators of drug function, response, efficacy, and safety through tissue analysis and protein detection.